Analyst Ratings For Puretech Health PLC (LON:PRTC)
Today, Peel Hunt raised its price target on Puretech Health PLC (LON:PRTC) to GBX 259 per share.
There are 5 buy ratings on the stock.
The current consensus rating on Puretech Health PLC (LON:PRTC) is Buy (Score: 3.00) with a consensus target price of GBX 245 per share, a potential .
Some recent analyst ratings include
- 1/5/2017-Jefferies Group LLC Reiterated Rating of Buy.
- 12/21/2016-Numis Securities Ltd Reiterated Rating of Buy.
- 12/21/2016-N+1 Singer Reiterated Rating of Buy.
- 12/21/2016-Liberum Capital Reiterated Rating of Buy.
About Puretech Health PLC (LON:PRTC)
PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets. This segment includes subsidiary companies, which include Vedanta Biosciences, Inc., Gelesis, Inc., Akili Interactive Lab, Inc., Tal Medical, Inc., Karuna Pharmaceuticals, Inc., Entrega Inc. and Follica Incorporated. Businesses in the project phase businesses segment are those whose activities are focused on financing, sourcing and creating new product candidates and newly created businesses whose technologies are in the process of validation. This segment includes subsidiary companies, which include The Sync Project Inc., Sonde Health, Inc., Commense Inc., Alivio Therapeutics, Inc., Vor Biopharma Inc., Enlight Biosciences, LLC, Mandara Sciences, LLC and Knode Inc.
Recent Trading Activity for Puretech Health PLC (LON:PRTC)
Shares of Puretech Health PLC closed the previous trading session at 115.35 down -1.15 -0.99% with 40,453 shares trading hands.